Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome

Blood

Volumn 121, Issue 16, 2013, Pages 3181-3184

  Toki, Tsutomu ^a   Kanezaki, Rika ^a   Kobayashi, Eri ^b   Kaneko, Hiroshi ^b   Suzuki, Mikiko ^b   Wang, RuNan ^a   Terui, Kiminori ^a   Kanegane, Hirokazu ^c   Maeda, Miho ^d   Endo, Mikiya ^e   Mizuochi, Tatsuki ^f   Adachi, Souichi ^g   Hayashi, Yasuhide ^h   Yamamoto, Masayuki ^b   Shimizu, Ritsuko ^b   Ito, Etsuro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h Gumna Children S Medical Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; TRANSCRIPTION FACTOR GATA 1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BHK CELL LINE; CELL PROLIFERATION; DOWN SYNDROME; GENE DELETION; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; MYELOPOIESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSIENT ABNORMAL MYELOPOIESIS; BLOOD; CHILD; GENETICS; LEUKEMOID REACTION; METABOLISM; PATHOLOGY;

CELL PROLIFERATION; CHILD; DOWN SYNDROME; GATA1 TRANSCRIPTION FACTOR; HUMANS; LEUKEMOID REACTION; MEGAKARYOCYTES; SEQUENCE DELETION;

MLCS; MLOWN;

EID: 84879247882     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-405746     Document Type: Article

References (19)

1. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol. 1992;9(2):139-149.
2. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277-282.
3. Hitzler JK. Acute megakaryoblastic leukemia in Down syndrome. Pediatr Blood Cancer. 2007;49 (7 Suppl):1066-1069.
4. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009; 113(12):2619-2628.
5. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002; 32(1):148-152.
6. Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102(8):2960-2968.
7. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102(3):981-986.
8. Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004; 103(8):3242-3243.
9. Hama A, Yagasaki H, Takahashi Y, et al. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome. Br J Haematol. 2008;140(5):552-561.
10. Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood. 2005; 106(4):1223-1231.
11. Shimizu R, Kobayashi E, Engel JD, Yamamoto M. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. Genes Cells. 2009;14(9): 1119-1131.
12. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005; 37(6):613-619.
13. Kanezaki R, Toki T, Terui K, et al. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood. 2010;116(22):4631-4638.
14. Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res. 1987;15(17): 7155-7174.
15. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16(13):3965-3973.
16. Toki T, Kanezaki R, Adachi S, et al. The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia. Leukemia. 2009;23(1):95-103.
17. Kadri Z, Shimizu R, Ohneda O, et al. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. PLoS Biol. 2009;7(6):e1000123.
18. Klusmann JH, Godinho FJ, Heitmann K, et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev. 2010;24(15): 1659-1672.
19. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004; 279(4):2737-2746.